BMO Capital analyst James Fotheringham raised his price target on Goldman Sachs (GS) to $245 after the company's Q1 revenue beat, saying it is "back to stealing market share in its core business" as its FICC - fixed income, currencies, and commodities - trading rose 23% vs. a 4% decline for peers. The analyst adds that while Goldman Sachs will continue to experience positive operating leverage, its valuation relative to Morgan Stanley (MS) cannot be justified, favoring the latter based on its greater exposure to higher-multiple asset management businesses. Fotheringham keeps his Market Perform rating on Goldman Sachs.

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.  1... To see the rest of the story go to thefly.com. See Story Here

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here

Notable gainers among liquid option names this morning include UnitedHealth (UNH) $475.73 +30.10, Super Micro (SMCI) $914.90 +32.15, Humana (HUM) $324.54 +9.90, Morgan Stanley (MS) $89.42 +2.43, and Cencora Inc (COR) $238.39 +4.18.

BMO Capital raised the firm's price target on Goldman Sachs to $360 from $349 and keeps a Market Perform rating on the shares. The analyst cites the company's Q1 earnings beat driven by its Global Banking & Markets segment, with higher-than-previously modeled revenues and lower tax expenses more than offsetting higher expected compensation costs. BMO Capital is also raising its FY24 EPS view by $37.17 from $32.49 and its FY25 view to $38.62 from $37.53 for Goldman Sachs. The firm adds however that the stock's valuation already incorporates the benefits of an anticipated capital markets recovery.

Check out this morning's top movers from around Wall Street, compiled by The Fly. HIGHER - Macatawa... To see the rest of the story go to thefly.com. See Story Here

HSBC analyst Saul Martinez raised the firm's price target on Goldman Sachs to $470 from $460 and keeps a Buy rating on the shares. The analyst increased estimates following Goldman's "broad-based beat" in Q1. Though macro uncertainty remains, higher investment banking fees and "self-help" should contribute to ongoing return on tangible common equity improvements, the analyst tells investors in a research note. HSBC calls Goldman its preferred vehicle to invest in improved capital markets activity.

As previously reported, Argus upgraded Goldman Sachs to Buy from Hold with a $465 price target. The company's Q1 results demonstrated the considerable strengths of the Goldman franchise during an investment banking upturn, the analyst tells investors in a research note, stating that while the investment banking environment offered a few false rebounds in 2023, the current surge appears to have staying power as equity and debt underwriting showing sequential improvement. Goldman's recent exit from several consumer businesses, which produced significant losses for the firm, also removes a headline risk and allows its management to refocus on core strengths in capital markets, Argus added.